1-Methyltryptophan

1-Methyltryptophan is a chemical compound that is an inhibitor of the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase. It is a chiral compound that can exist as both - and -enantiomers.
The -isomer inhibits IDO weakly but also serves as an enzyme substrate.
The -isomer does not inhibit IDO at all, but it can inhibit the IDO-related enzyme IDO2 and restore mTOR signaling in cells starved of tryptophan due to IDO activity. -1MT is also known as indoximod and it was in clinical trials for cancer treatment, such as for advanced melanoma, in 2017.
A U.S. patent covering salt and prodrug formulations of indoximod was issued to NewLink Genetics on August 15, 2017, providing exclusivity until at least 2036.